title: Trabectedin in advanced soft tissue sarcoma: case series.
abstract: The prognosis of advanced soft tissue sarcomas (STS) is poor. The median overall survival (OS) is 6 months in unresectable and metastatic STS that progress after treatment with anthracyclines and ifosfamide. Trabectedin is an alkylating agent, effective in advanced STS, especially in leiomyosarcoma and liposarcoma. In the present study, the effectiveness and safety of trabectedin was retrospectively evaluated in 8 unresectable and metastatic STS patients. Their median age was 47 years. The median progression free survival (PFS) was 3.75 months and the median OS 15 months in relapse or progression after anthracyclines and/or ifosfamide. Toxicities were mainly hematologic. In the present study, trabectedin showed efficacy in different histological subtypes of sarcomas like liposarcoma and leiomyosarcoma.
authors.affiliation: Department of Medical Oncology, Ataturk Education and Research Hospital, Ankara, Turkey. drmutdemirci@gmail.com
authors.forename: U
authors.initials: U
authors.lastname: Demirci
authors.forename: S
authors.initials: S
authors.lastname: Buyukberber
authors.forename: T
authors.initials: T
authors.lastname: Yetisyigit
authors.forename: O
authors.initials: O
authors.lastname: Dizdar
authors.forename: M
authors.initials: M
authors.lastname: Benekli
authors.forename: N
authors.initials: N
authors.lastname: Alkis
authors.forename: U
authors.initials: U
authors.lastname: Coskun
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D004149:Dioxoles / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality; D044005:Tetrahydroisoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D000077606:Trabectedin
chemical_list: D018906:Antineoplastic Agents, Alkylating; D004149:Dioxoles; D044005:Tetrahydroisoquinolines; D000077606:Trabectedin